Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Peg, Esper"'
Publikováno v:
Clinical journal of oncology nursing. 25(3)
Background Brachytherapy is a well-established and effective primary treatment modality for low- and favorable intermediate-risk prostate cancers. Although the benefits of brachytherapy in unfavorable intermediate- and high-risk prostate cancers have
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d025efe6fe4fb28b4f6b09c63d0702cc
https://pubmed.ncbi.nlm.nih.gov/34019017
https://pubmed.ncbi.nlm.nih.gov/34019017
Autor:
Suzette Walker, Peg Esper
Publikováno v:
Journal of the American Association of Nurse Practitioners. 27:308-312
Oncology quality measures provide an important tool to evaluate care received by cancer patients. These measures are frequently addressed by oncology nurse practitioners (NPs). NP documentation of quality oncology practice initiative (QOPI) measures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de9daea4504b6cbb9c7e67522b2ac4c9
https://doi.org/10.1002/2327-6924.12169
https://doi.org/10.1002/2327-6924.12169
Autor:
Peg Esper, Ashley Przybylyski
Publikováno v:
Clinical journal of oncology nursing. 20(3)
Background Adult patients with cancer receiving antineoplastic, targeted, and other immunosuppressive therapies are at risk for severe side effects. Studies link posterior reversible encephalopathy syndrome (PRES) with immunosuppressants used for pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53dbde27a5fd09d88ef41868e11218ac
https://pubmed.ncbi.nlm.nih.gov/27206297
https://pubmed.ncbi.nlm.nih.gov/27206297
Autor:
Peg Esper
Publikováno v:
Seminars in Oncology Nursing. 28:170-179
Objectives Treatment options for advanced renal cell carcinoma have increased dramatically over the past 6 years as a result of improved understanding of the biology of renal cancer and the development of therapies to target pathways relevant to tumo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a60bab49cc6a0141a9a31df8190742e6
https://doi.org/10.1016/j.soncn.2012.05.006
https://doi.org/10.1016/j.soncn.2012.05.006
Autor:
Michael N. Neuss, Peg Esper, Martha Polovich, Terry Gilmore, Kristine B. LeFebvre, Lisa Schulmeister, Joseph O. Jacobson
Publikováno v:
Journal of Oncology Practice. 8:2-6
In November 2009, the American Society of Clinical Oncology (ASCO) and the Oncology Nursing Society (ONS) jointly published a set of 31 voluntary chemotherapy safety standards for adult patients with cancer, as the end result of a highly structured,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c68bd278a24fd7bc2c7862eb04962272
https://doi.org/10.1200/jop.2011.000339
https://doi.org/10.1200/jop.2011.000339
Autor:
Peg Esper
Publikováno v:
Seminars in Oncology Nursing. 26:168-174
Objectives To discuss issues related to symptom clusters in patients living with advanced cancer. Data Sources Research and review articles. Conclusion The importance for symptom cluster evaluation in oncology has been documented; however, there rema
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2071ec207163bb624e3a534614d4becc
https://doi.org/10.1016/j.soncn.2010.05.002
https://doi.org/10.1016/j.soncn.2010.05.002
Autor:
Peg Esper
Publikováno v:
Clinical Journal of Oncology Nursing. 13:547-554
Two fully human monoclonal antibodies (mAbs) that target cytotoxic T lymphocyte-associated antigen 4 (CTLA4), tremelimumab and ipilimumab, are in clinical development for the treatment of advanced cancers. The investigational agents enhance T-cell ac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c739720ef56e92420846e7dc3c180df3
https://doi.org/10.1188/09.cjon.547-554
https://doi.org/10.1188/09.cjon.547-554
Autor:
Guihua Jiang, Peg Esper, Thomas Braun, James J. Mulé, Joel Whitfield, Bruce G. Redman, Blake J. Roessler, Alfred E. Chang
Publikováno v:
Journal of Immunotherapy. 31:591-598
Twenty-four subjects with metastatic melanoma were treated on a randomized Phase Ib trial evaluating an autologous tumor lysate-pulsed dendritic cell (DC) vaccine with or without interleukin (IL)-2. The vaccine consisted of autologous DCs obtained fr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b621ff0f926e2b9180fc5b753a216678
https://doi.org/10.1097/cji.0b013e31817fd90b
https://doi.org/10.1097/cji.0b013e31817fd90b
Autor:
Neeraj Agarwal, Peg Esper, Sarah Scarlett, Joseph Merriman, David Gill, Wolfram E. Samlowski, Archana M. Agarwal, Stephanie Daignault, Katherine A. Skinner, Bruce G. Redman, Kinjal Parikh, Kenneth F. Grossmann, Alli M. Straubhar, Michael Toole, Ajjai Alva, Aaron M. Udager, David D. Stenehjem, Srinivas K. Tantravahi
Publikováno v:
Cancer immunology, immunotherapy : CII. 65(8)
In metastatic renal cell carcinoma (mRCC), survival benefit associated with objective response rates of 16–20 % with high-dose interleukin-2 (HDIL-2) is well established and discussed. Based on recently emerged data on efficacy of cancer immunother
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23ac787796ab2cdc68296925d9f87ed3
https://pubmed.ncbi.nlm.nih.gov/27277816
https://pubmed.ncbi.nlm.nih.gov/27277816
Autor:
Peg Esper, Debra E. Heidrich
Publikováno v:
Seminars in Oncology Nursing. 21:20-28
Objectives To review the four sets of symptom clusters commonly seen in patients with advanced illness, and their definitions, associated symptomatology, and management. Data sources Research and review articles and textbooks. Conclusion Symptoms of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d16260b98c7cf8adaba33870bd1cceca
https://doi.org/10.1053/j.soncn.2004.10.004
https://doi.org/10.1053/j.soncn.2004.10.004